Abstract
Multiple sclerosis (MS) is a disorder of the central nervous system (CNS). It is characterized by episodic and progressive neurological dysfunction resulting from inflammatory and autoimmune reactions, myelin loss, conduction block, oligodendrocyte pathology, gliosis, and axonal loss in CNS. Recent years have witnessed advances in better understanding the immune pathogenesis of MS, prompted by animal models, human pathological observations and MRI studies. There have been significant changes in the therapeutic regimens in MS, with an emphasis on preventative treatment of an ongoing disease process. Agents in use and in the research pipeline have mechanisms that act on various antiinflammatory and immunomodulatory properties, including blocking leukocyte migration into CNS and targeting chemoattraction. In addition, recent studies on the neurodegenerative components of MS have directed therapeutic trials to neuroprotection and neurorestoration. In this paper, we summarize the current understanding of the mechanisms of approved pharmacological agents and review the putative mechanisms and status of some important agents in clinical phase two or three trials in MS.
Keywords: Multiple sclerosis, autoimmunity, therapy, clinical trials
Central Nervous System Agents in Medicinal Chemistry
Title: Advances in the Immune Pathogenesis and Treatment of Multiple Sclerosis
Volume: 9 Issue: 1
Author(s): DeRen Huang and Alexander Rae-Grant
Affiliation:
Keywords: Multiple sclerosis, autoimmunity, therapy, clinical trials
Abstract: Multiple sclerosis (MS) is a disorder of the central nervous system (CNS). It is characterized by episodic and progressive neurological dysfunction resulting from inflammatory and autoimmune reactions, myelin loss, conduction block, oligodendrocyte pathology, gliosis, and axonal loss in CNS. Recent years have witnessed advances in better understanding the immune pathogenesis of MS, prompted by animal models, human pathological observations and MRI studies. There have been significant changes in the therapeutic regimens in MS, with an emphasis on preventative treatment of an ongoing disease process. Agents in use and in the research pipeline have mechanisms that act on various antiinflammatory and immunomodulatory properties, including blocking leukocyte migration into CNS and targeting chemoattraction. In addition, recent studies on the neurodegenerative components of MS have directed therapeutic trials to neuroprotection and neurorestoration. In this paper, we summarize the current understanding of the mechanisms of approved pharmacological agents and review the putative mechanisms and status of some important agents in clinical phase two or three trials in MS.
Export Options
About this article
Cite this article as:
Huang DeRen and Rae-Grant Alexander, Advances in the Immune Pathogenesis and Treatment of Multiple Sclerosis, Central Nervous System Agents in Medicinal Chemistry 2009; 9 (1) . https://dx.doi.org/10.2174/187152409787601923
DOI https://dx.doi.org/10.2174/187152409787601923 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: Cocaine and Cerebral Small Vessel: Is it a Negative Factor for Intravenous Thrombolysis?
Current Vascular Pharmacology Micro- and Nano-particulate Strategies for Antigen Specific Immune Tolerance to Treat Autoimmune Diseases
Pharmaceutical Nanotechnology Hypertension in Pregnancy: Pathophysiology & Management Strategies
Current Pharmaceutical Design Metabolic Profiling in Multiple Sclerosis and Other Disorders by Quantitative Analysis of Cerebrospinal Fluid Using Nuclear Magnetic Resonance Spectroscopy
Current Pharmaceutical Biotechnology Biologics for ANCA-Associated Vasculitis
Inflammation & Allergy - Drug Targets (Discontinued) How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease
Current Drug Targets Human Immunodeficiency Virus-Mononuclear Phagocyte Interactions:Emerging Avenues of Biomarker Discovery, Modes of Viral Persistence and Disease Pathogenesis
Current HIV Research Microbes, Immunity and Multiple Sclerosis
Current Immunology Reviews (Discontinued) Other Potential Therapeutic Targets in Thyroid Orbitopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Targeted Therapy in Colorectal Cancer: Current Status and Future Challenges
Current Medicinal Chemistry Update on the Use of Biologics in Vasculitides
Current Pharmaceutical Biotechnology Cognitive, Psychological and Psychiatric Effects of Ionizing Radiation Exposure
Current Medicinal Chemistry Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets Concurrent Use of Antiretrovirals and Anticonvulsants in Human Immunodeficiency Virus (HIV) Seropositive Patients
Current Pharmaceutical Design A Review on Clinical Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Natalizumab: A Humanized Anti-α4 Integrin Monoclonal Antibody
Current Drug Metabolism Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets Targeted Radiotherapy for Malignant Gliomas
Current Drug Discovery Technologies An Update of the Published Reports on Biologics Use for Psoriasis and the Reimbursement Status in Asia-Pacific Region
Current Rheumatology Reviews Small Ruminant Lentiviruses and Human Immunodeficiency Virus: Cousins that Take a Long View
Current HIV Research Do HIV-Infected Immigrants Initiating HAART have Poorer Treatment-Related Outcomes than Autochthonous Patients in Spain? Results of the GESIDA 5808 Study
Current HIV Research